ArticleMolecular psychiatry2004
GM1 ganglioside regulates the proteolysis of amyloid precursor protein.
Article in Molecular psychiatry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 99 citations in OpenAlex.
- The Human Ganglioside Interactome in Live Cells Revealed Using Clickable Photoaffinity Ganglioside Probes.Journal of the American Chemical Society · 2024Article
- Novel insights into brain lipid metabolism in Alzheimer's disease: Oligodendrocytes and white matter abnormalities.FEBS open bio · 2024Review
- Ganglioside GM1 and the Central Nervous System.International journal of molecular sciences · 2023Review
- Gemfibrozil-Induced Intracellular Triglyceride Increase in SH-SY5Y, HEK and Calu-3 Cells.International journal of molecular sciences · 2023Article
- Brain lipidomics: From functional landscape to clinical significance.Science advances · 2022Review
- Methylxanthines Induce a Change in the AD/Neurodegeneration-Linked Lipid Profile in Neuroblastoma Cells.International journal of molecular sciences · 2022Article
- Peripheral Delivery of Ganglioside GM1 Exacerbates the Pathogenesis of Alzheimer's Disease in a Mouse Model.Neuroscience bulletin · 2022Article
- Alzheimer's disease as an autoimmune disorder of innate immunity endogenously modulated by tryptophan metabolites.Alzheimer's & dementia (New York, N. Y.) · 2022Article
- The impact of the glycan headgroup on the nanoscopic segregation of gangliosides.Biophysical journal · 2021Article
- The Role of Neurovascular System in Neurodegenerative Diseases.Molecular neurobiology · 2020Review
- Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts.Scientific reports · 2020Article
- Protein Aggregation and Dysfunction of Autophagy-Lysosomal Pathway: A Vicious Cycle in Lysosomal Storage Diseases.Frontiers in molecular neuroscience · 2020Article
- Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers.International journal of molecular sciences · 2019Review
- Alzheimer's disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline.Brain pathology (Zurich, Switzerland) · 2019Review
- Detection of β-Amyloid by Sialic Acid Coated Bovine Serum Albumin Magnetic Nanoparticles in a Mouse Model of Alzheimer's Disease.Small (Weinheim an der Bergstrasse, Germany) · 2018Article
- Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention.Journal of lipid research · 2017Review
- Endogenous Brain Lipids Inhibit Prion Amyloid FormationJournal of virology · 2017Article
- The Pathogenic Role of Ganglioside Metabolism in Alzheimer's Disease-Cholinergic Neuron-Specific Gangliosides and Neurogenesis.Molecular neurobiology · 2017Review
- APP Function and Lipids: A Bidirectional Link.Frontiers in molecular neuroscience · 2017Review
- Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plaques containing amyloid beta-peptides (Abeta) are a major feature in Alzheimer's disease (AD), and GM1 ganglioside is an important component of cellular plasma membranes and especially enriched in lipid raft. GM1-bound Abeta (GM1/Abeta), found in brains exhibiting early pathological changes of AD including diffuse plaques, has been suggested to be involved in the initiation of amyloid fibril formation in vivo by acting as a seed. However, the role of GM1 in amyloid beta-protein precursor (APP) processing is not yet defined. In this study, we report that exogenous GM1 ganglioside promotes Abeta biogenesis and decreases sAPPalpha secretion in SH-SY5Y and COS7 cells stably transfected with human APP695 cDNA without affecting full-length APP and the sAPPbeta levels. We also observe that GM1 increases extracellular levels of Abeta in primary cultures of mixed rat cortical neurons transiently transfected with human APP695 cDNA. These findings suggest a regulatory role for GM1 in APP processing pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.